The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Open accessAbstract
mRNA vaccines have the potential to tackle many unmet medical needs that are unable to be addressed with conventional vaccine technologies. A potent and well-tolerated delivery technology is integral to fully realizing the potential of mRNA vaccines. Pre-clinical and clinical studies have demonstrated that mRNA delivered intramuscularly (IM) with first-generation lipid nanoparticles (LNPs) generates robust immune responses. Despite progress made over the past several years, there remains significant opportunity for improvement, as the most advanced LNPs were designed for intravenous (IV) delivery of siRNA to the liver. Here, we screened a panel of proprietary biodegradable ionizable lipids for both expression and immunogenicity in a rodent model when administered IM. A subset of compounds was selected and further evaluated for tolerability, immunogenicity, and expression in rodents and non-human primates (NHPs). A lead formulation was identified that yielded a robust immune response with improved tolerability. More importantly for vaccines, increased innate immune stimulation driven by LNPs does not equate to increased immunogenicity, illustrating that mRNA vaccine tolerability can be improved without affecting potency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which are known to have significantly higher delivery efficiency in hepatocytes after intravenous (i.v.) injection31 or in muscle cells after intramuscular (i.m.) injection.32”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [32]
In the citing paper
“Based on these observations, Moderna has developed an ionizable lipid (namely Lipid H, SM-102), whose tail adopts larger branches which in turn increases potency, and whose introduced ester bonds increase biodegradability (Fig. 7).290,291”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [291]
In the citing paper
“All three major players in the mRNA vaccine field have previously optimized so-called lipid nanoparticles (LNPs), constructs that typically consist of an ionizable lipid and one or more helper lipids to improve LNP stability and promote endosomal escape upon cellular uptake [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“For Moderna's LNP formulation, Hassett et al. reported that the SM-102 lipid was selected based on its improved tolerability profile in non-human primates, as evidenced by a reduced local reactogenicity (e.g., edema and erythema) and lowest induction of systemic cytokine responses (e.g., IL-6) [13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“the usage of the SM-102 lipid in Moderna's mRNA-1273 vaccine was found to outperform Onpattro's MC3 LNPs for the intramuscular (i.m.) delivery of mRNA in rodents and non-human primates, given its improved tolerability and higher endosomal escape efficiency [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“Endosomal escape can be increased by optimizing the pKa values of ionizable lipids66,76–78,88,100,140.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“To improve the biocompatibility of lipid nanoparticles, biodegradable lipids can be applied76–78,108,179.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“Moreover, the delivery efficacy of mRNA could be improved, for example, by rational design of lipids through modulation of head groups and hydrophobic tails to increase cellular uptake and endosomal escape of lipid nanoparticle–mRNA formulations64,66,76–78,88,97,100,114,140,141.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Lanciotti, R. S., Kosoy, O. L., Laven, J. J., Velez, J. O., Lambert, A. J., Johnson, A. J., Stanfield, S. M., & Duffy, M. R. (2008) · Emerging infectious diseases · doi:10.3201/eid1408.080287 · Cited by 2,173
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“8.(11,13,23) However, the best lipids with respect to protein expression after IV administration generally had lower pKas than the best lipids for protein expression after IM administration.”
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Edward Jenner and the History of Smallpox and Vaccination
Riedel, S. F. (2005) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2005.11928028 · Cited by 965
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Self-citationZika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 918
New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery
Valeur, E. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00911
Seok, J., Jung, S., Han, Y. G., Park, A., Kim, J. E., Song, Y. J., Yu, C. H., Yun, H., Gu, S. H., Lee, S., et al. (2024) · Journal of the Korea Institute of Military Science and Technology · doi:10.9766/kimst.2024.27.1.116
Liposomes as DNA, mRNA and oligonucleotide delivery vectors
Nele, V., Campani, V., & Rosa, G. D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15491-1.00012-2
Claisen Self-Condensation of Lactones in the Synthesis of Ionizable Lipids
Nabi, A. A., Atmuri, N. D. P., Arnold, D., Saadati, F., Tran, H., Adak, T., Dake, G. R., & Ciufolini, M. A. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c01193
Hillery, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28934-7.00005-4
Yambadi, S., & Bakshi, V. (2024) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.14.3.59
Fluoroamphiphiles for enhancing immune response of subunit vaccine against SARS-CoV-2
Li, Y., Kang, Z., Zhang, X., Sun, Y., Han, Z., Zhang, H., Liu, Z., Liang, Y., Zhang, J., & Ren, J. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114528
Immune Responses to mRNA Vaccine
Exposito, J., Monge, C., Arruda, D. C., & Verrier, B. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch2
Nanomedicine’s Role in the COVID-19 Vaccine Development and Optimization
Kumar, J., Malhotra, J., Yadav, A. S., & Bhati, A. S. (2024) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-72467-1_3
Shaikh, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-7292-6_23
mRNA vaccines: The new frontier
Yan, Z., Yang, M. J., Tian, E., & Lai, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00021-8
Fant, P., Laurent, S., Désert, P., Combadière, B., Palazzi, X., Choudhary, S., Gervais, F., Broudic, K., Rossi, R., & Gauthier, B. E. (2025) · Toxicologic Pathology · doi:10.1177/01926233251326089
Immunological Properties of Adjuvants
Duthie, M. S., & Reed, S. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00151-4
Merck en la administración de medicamentos
Aisenbrey, E. A., & Flores, A. (2023) · doi:10.22201/iim.rma.2023.3.22
Lipid Nanoparticle Preparations for Diverse Drug Administrations
Liu, S. (2025) · International Journal of Biology and Life Sciences · doi:10.54097/qd03cp44
Yu, T., Xing, J.-H., Zhuang, X., & Tian, M. (2025) · Virology Journal · doi:10.1186/s12985-025-02787-7
Melnikova, N. B., Zamyshlyayeva, O. G., Kamorin, D. M., Kazantsev, O. A., Simagin, A. S., Malygina, D., Соловьева, А. Г., Mitroshina, Е. V., & Vedunova, M. V. (2025) · ChemistrySelect · doi:10.1002/slct.202501359
Gene Delivery for Cancer Immunotherapy
Wang, C., & Deng, H. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837675739-00159
Novel approaches to immuno-oncology
Chen, R., & Su, F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00047-3
Opposing impacts of DNA polyplex crosslinking on delivery efficiency and vaccine responses
Uchida, S. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102656
Son, J., Yoo, H., Park, J., Park, H., Chong, S., Lee, J., Kim, J., Park, E., Bae, S.-H., Kang, S.-H., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102697
Toyonaga, H., Cheng, L., & Tanaka, H. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00982
Exploring the impact of nucleotide length on lipid nanoparticle structure and properties
Hammel, M., Fan, Y., Kim, L. J., Zang, N., Xiao, B., Caliò, A., Yen, C., & Hura, G. L. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126944
Lipid Nanoparticles for Nucleic Acid Delivery and Gene Therapy: A Comprehensive Review
Lynn, S. P. (2025) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.918
Uddin, M. S., Faisal, M. R., Hossain, A. A., Hossain, A. A., Bristy, N. J., Fatama, M. U., Koko, M. A. R., & Islam, T. (2025) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2025.24.2.0971
Chen, C. H., Dane, E. L., Oag, S., Sand, E., Andersson, P. U., Bak, A., & Zhou, L. (2025) · Organic & Biomolecular Chemistry · doi:10.1039/d5ob01888a
Introduction to antiviral nanomaterials: Mechanisms and applications
Ahmed, R., Akinnawo, C. A., Chikukwa, M. T. R., Fielding, B. C., & Dube, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33002-5.00002-6
Melnikova, N. B., Zamyshlyayeva, O. G., Kamorin, D. M., Kazantsev, O. A., Simagin, A. S., Belikov, A., Соловьева, А. Г., Marasanova, E. A., Mitroshina, Е. V., & Vedunova, M. V. (2025) · Polymer Bulletin · doi:10.1007/s00289-025-06197-1
Whitehead, K. A. (2025) · Nature Chemical Engineering · doi:10.1038/s44286-025-00332-5
Nanoimmunotherapy and nanomedicine
Rahvar, M., Gholami, L., & Rahmani, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21521-6.00004-1
The Clearance of Human Cytomegalovirus Using CRISPR/Cas9 RNA Lipid NanoparticlesPreprint
Lau, Y. M. A., Pang, J., Jiang, M. Q., Sun, Y., Knaggs, K. L. M., Tilstra, G., Oproescu, A.-M., Couture‐Senécal, J., Manning, A. M., Maaieh, R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.17.694960
mRNA-based vaccines: Rational antigen design, delivery optimization, and immune modulation
Liu, S., Shi, H., Dai, D., Tian, T., Duan, X., Sun, J., Xu, W., Yin, X., Xie, Y., & Song, X. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112312
Ahmed, I., Martinez, Q., McRae, S., & Dharmalingam, A. (2026) · Preprints.org · doi:10.20944/preprints202601.1387.v1
Amphiphilic guanidine-based lipids enhance mRNA delivery and immune activation
Wei, Q., Li, R., Fan, J., Xu, M., Yuan, P., Liu, J., Wang, Q., Shen, Y., Slater, N. K. H., & Tang, J. (2026) · Biomaterials Science · doi:10.1039/d6bm00068a
Abbadi, D., Katsara, O., McConnell, R., Walters, B., Blanco, K. G., Canfrán‐Duque, A., Dornbaum, S., Andrews, J. J., & Schneider, R. J. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.033
Evdokimou, M., Alaqabani, H., Hussain, M., & Perrie, Y. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115034
Rapid growth and thematic shifts in mRNA therapeutics research catalyzed by the COVID-19 pandemic
Annadurai, P. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05173-4
Ruano, M., Ozichi, C., Bedford, M. R., Mullen, A. B., Kelemen, D. W., & Ferro, V. A. (2026) · Exploration of BioMat-X · doi:10.37349/ebmx.2026.101362
LNP-mRNA immunogenicity and toxicity
Thalla, M., Pasika, S. R., Bulusu, R., Reddy, D. S., Mundrathi, V., & Shukla, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00008-2
AI-driven advancements in vaccine development: From discovery to global deployment
Ali, A. M., Mushtaq, D., Qadri, S., Saman, S., Almuqdadi, H. T. A., Hindi, A. A., Neeraj, Jasim, O. M., Sharma, A., & Qazi, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44430-2.00001-3
Zhang, X., Liao, Y., Hong, X., Xiao, Y., & Zeng, X. (2026) · Science China Chemistry · doi:10.1007/s11426-025-3182-6
Lipid nanoparticles for mR delivery: from rational design and manufacturing to clinical translation
Yu, J., Yan, X., & Yu, Y. (2026) · Creative Science · doi:10.55674/cs.v18i2.265802
Adjuvant intrinsic dendritic cells targeting vaccines
Ceglia, V. (2021) · theses.fr (ABES) · doi:10.70675/759176f1zd3faz43d3zab70z79d7079deee8
Linares-Fernández, S. (2021) · theses.fr (ABES) · doi:10.70675/17ec09cezeb11z45f7z8529z7ffbf89d664a
Vectorisation d'ARN par voie orale et parentérale
Stalder, T. (2024) · theses.fr (ABES) · doi:10.70675/d509592fzbb96z4f17zb286z5040de22fd65
Hengelbrock, A., Knierim, L., Schmidt, A., & Strube, J. (2026) · Processes · doi:10.3390/pr14091351
Advanced lipid nanoparticles for targeted nucleic acid delivery
Deng, Y., Chen, M., Zhou, X., Luo, T., Guo, J., Giles, A., Mourin, T. T., & Chen, G. (2026) · Nano Research · doi:10.26599/nr.2026.94908809
Metabolism of the ionizable lipid SM-102 in liver microsomes, 2D hepatocytes, and 3D liver spheroids
Sun, B., Jin, Z., Li, X., Xiao, X., Jiang, Z., Xie, W., Zhang, L. W., & Deng, P. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100323
Computational Design of mRNA-Based Cancer Immunotherapies
Kovačić, D., Huseinbegović, S. I., Muratović, A. K., & Jahibasic, M. (2026) · Springer eBooks · doi:10.1007/978-3-032-20428-8_2
Batista-Zauli, M. F., Brasil, M. E. C. G., de Almeida-Júnior, C. R., de Abreu, B. G. S., dos Santos, N. S. A., Ricci, M. F., & Teixeira, S. M. R. (2026) · Microorganisms · doi:10.3390/microorganisms14051112
Segalla, G. (2026) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/q9fgvp96 · Cited by 1
Enhanced Intramuscular mRNA Activity of Peptide–Lipid Nanoparticles with Hydrophobized Head Groups
Weidinger, E., Burghardt, T., Obeser, L., Germer, J., Pöhmerer, J., Yazdi, M., Höhn, M., Merk, D., & Wagner, E. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00181
Nanoparticle-Based Antigen Delivery: Advancing Immunization Strategies against Infectious Pathogens
Patra, S., Pathan, N. S., Karpe, Y. A., & Gajbhiye, V. (2026) · Biomaterials Research · doi:10.34133/bmr.0385
Xu, Y., Zhang, X.-B., & Zhang, J.-P. (2026) · Human Gene Therapy · doi:10.1177/10430342261454725
Chen, J., Zhang, X., Zhang, J. N., Ren, H., Xie, J., & Ma, R. (2026) · Current Medicinal Chemistry · doi:10.2174/0109298673413607251209115328
Wang, X., Li, C., Wang, S., Liu, C., Shi, J., Xu, W., Zhou, S., Xu, S., Shang, Y., & Li, J. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s613251
Nelluri, K. D. D., Rahaman, S. A., Rohith, P. S., Alaparthi, B., Kommoju, M., Nirmala, N. V., Befathima, S., Srivastava, S., Ali, S., & Sahu, R. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12180-4
Molecular Self-Assemblies for Nanomedicine Applications
Miyata, K. (2026) · Kobunshi · doi:10.1295/kobunshi.75.7_307
Existing and Engineered Excipients as Product-Enabling Materials
Almarsson, Ö., & Hickey, M. B. (2026) · International Journal of Pharmaceutical Excipients · doi:10.66617/001c.164294
Self-citationAnalytical Characterization and Stability Assessment of RNA-Based Vaccines
Alasmari, H., Alghannam, S. F., Almoammar, H., Alrabiah, D. K., Harthy, S. A., Alyamani, E. J., Alyahya, S. A., Alkhrayef, M. N., Fallatah, M., Al‐Khaldi, S., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070790
Vadovics, M., Pampena, M. B., Lam, K., Lundgreen, K. A., Muramatsu, H., Sárközy, A., Ábrahám, E., Lipinszki, Z., Bates, P. F., Betts, M. R., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102999
Current progress in developing mRNA-lipid nanoparticle vaccines against human bacterial pathogens
Pullinger, B., Harbison-Price, N., Sebina, I., Na, J., Belz, G. T., & Walker, M. J. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00138-26
History, introduction, properties, and applications of protein-based drug delivery
Nguyen, U. N. P., & Dang, T. T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33639-3.00017-9
Bian, H., Tse, W. W., Huang, G., & Liu, S. (2026) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbag019
Pulmonary Delivery of Self-Amplifying RNA: Balancing Inflammation and Durable Transgene Expression
Sun, Q., Cui, X., Li, H., Vervaeke, P., Lienenklaus, S., Gillon, O., Sutter, E. D., Helsmoortel, C., Devriendt, B., Snoeck, J., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c00709
Shao, J., Zhang, C., She, G., Qin, T., Zhang, J. C., Fang, M., Zhao, D., Wang, L., 夏丽娟, Yang, Q., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1849279
Han, X., Wang, W., & Wang, Y. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.179648
Yuan, Y., Zeng, Y., Zhu, M., Sun, Z., Xu, W., 胡慭然, Liu, G., Shen, M., Yang, C., & Gao, D. (2026) · Vaccines · doi:10.3390/vaccines14080708
Navigating Lipid Nanostructure Design Space Through Continuous Microfluidic Automation
Diggines, B., Fletcher, M. F., Bibrowski, M., Samnuan, K., Chen, R., Peeler, D. J., Abouselo, A., Hunter, M. R., Stevens, M. M., Brooks, N. J., et al. (2026) · Advanced Materials · doi:10.1002/adma.74165
Catholic Doctrine Supports Religious Exemption to COVID-19 Vaccine Mandates
McKenna, K. C., McGovern, C., & Sabol, M. (2026) · The Linacre Quarterly · doi:10.1177/00243639261456061
Sriram, V., Phatangare, V., & Lee, J. (2026) · Biomaterials Science · doi:10.1039/d6bm00568c
mRNA vaccines targeting HPV E6/E7: A new frontier in cervical cancer immunotherapy
Aftabsavad, S., Arashkia, A., Shokrgozar, M. A., Rahimi, A., & Karimipoor, M. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105520
Cascading attrition of in vivo CAR-T therapy: From systemic delivery failure to functional collapse
Rao, H., Xu, S., Chen, J., & Guo, Z. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105521
Redox-responsive nanomaterials for mRNA delivery: From rational design to therapeutic applications
Li, M., Wang, Y., Gao, J., An, S., Tang, Z., & Tao, W. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115942
Zhang, X., Wang, L., He, W., Ren, Z., Zhang, C., Zhou, M., Wan, J., Zhao, J., & Zhao, L. (2026) · Veterinary Microbiology · doi:10.1016/j.vetmic.2026.111188
Ali, H., Farooq, M., Shah, U., Khan, B., & Malik, S. (2026) · Pharmacophore · doi:10.51847/4ylxcn8kfc
Stage‐Adapted Disease‐Modifying Therapy in Type 1 Diabetes
Ye, C., Jin, Z., & Hu, S. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71210
Engineering CAR‐Macrophages With Advanced Delivery Systems for Tissue Repair
Zhang, Y., Yu, J., Yuan, L., Fu, Z., Yao, Y., Chen, L., Chen, S., Aikemu, A., & Cui, X. (2026) · Advanced Science · doi:10.1002/advs.77234
RNA delivery to the corneal endothelium using charge-altering releasable transporters
Wang, S. K., Li, Z., Shah, S. H., Edwards, Q. A., Bouffard, R., Hines, E. S., Imventarza, J. A., Korte, S., Lawrence, M. S., Song, E., et al. (2026) · Science Advances · doi:10.1126/sciadv.ady8161
Tail length of triazine-based lipids influences blood clotting risk in vitro and in vivoPreprint
Ibnat, N., Masud, A. A., Mory, J., Funk, T., Mahmood, D. F. D., Wood, J. P., & Venditto, V. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.25.747137
Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies
Ko, D., Park, S., Nam, K.-H., Choi, J., & Lee, K. (2026) · Immune Network · doi:10.4110/in.2026.26.e31
Park, J., Lee, G., Lee, H., Kim, J., Kim, K., Kim, E., Lee, J., Lee, S., Youn, J., & Jang, Y. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103082
From cellular therapy to biologics: Non-viral delivery strategies for in vivo CAR-T engineering
Wu, S., Shen, Y., Tong, X., Nian, S., & Yang, P. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105587
Silva, M. C. C. D., & Pereira, J. (2025) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/l143898370
Bioactivatable conjugated nanocarriers for synergistic mRNA-mediated cancer immunotherapy
Nazeer, N., Gajjar, T. B., Hanumanthayya, M., Bainsal, N., Singhal, D., Smerat, A., Alsharif, K. F., Alzahrani, F. M., Alzahrani, K. J., & Singh, S. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.105029
Stephanie, F., Hussain, M., Evdokimou, M., Parkinson, J., Perrie, Y., & Coxon, G. D. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7434569
Linker-mediated single-transcript mRNA vaccine expressing virus-like particles of enterovirus D68
Kunishima, Y., Senpuku, K., Taniguchi, K., Kataoka-Nakamura, C., Hirai, T., & Yoshioka, Y. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.129136
Engineering Biology Beyond Single Genes: Advances and Challenges in Multiplex Genome Editing
Wang, L., Liu, Y., & Han, H. (2026) · Animal Research and One Health · doi:10.1002/aro2.70094
Immune memory engineering in mRNA therapeutics
Wen, J., Tao, W., & Zhou, X. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115370
Computer Learning Can Streamline Development of Lipid Nanoparticle Vaccine Delivery ConstructsPreprint
Rosenn, E. H., Engel, M., Munarova, V., Lipshitz, M., Edell, N., Halperin, D., & Fox, E. (2026) · ChemRxiv · doi:10.26434/chemrxiv.15009316/v1
Synthesis and optimization of ionizable lipids for RNA delivery
Wu, B., Lu, X., Padilla, M. S., Dharmesh, E., Xu, Y., Mitchell, M. J., & Han, X. (2026) · Chem · doi:10.1016/j.chempr.2026.103244
Hong, J., Lim, J., Park, M., Song, J., Lee, B. J., Park, M., Shin, M., Seo, H., Kang, H. J., Kim, B., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.21.753074
Ma, M., Xie, S., Zhang, H., Ma, H., Wang, T., Wang, X., Zhao, Z., Han, H., Zhang, Y., He, J., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c12073
Beyond correlation and causation: epistemic caution, anomalous findings, and COVID-19 vaccine safety
Siebner, A. S., Rubio‐Casillas, A., Raszek, M., Cowley, D. E., Fabrowski, M., Piscopo, M., Brogna, C., Uversky, V. N., Redwan, E. M. M. M., & Genova, S. (2026) · Philosophy Ethics and Humanities in Medicine · doi:10.1186/s13010-026-00232-3
van der Walle, C. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45791-3.00002-0
Jeong, H., Park, C. H., Kim, B., Doh, J., & 구희범 (2026) · Lab on a Chip · doi:10.1039/d6lc00477f
The expression window as a safety parameter for mRNA medicines
Tani, H. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118513
Al-Hareth, Z., & López‐Camacho, C. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70183
Ahn, J.-H., Lee, N.-Y., Bae, H.-J., Kim, J., Kwak, J., Roh, G., Bae, S., Lee, J., Nam, J.-H., Kim, J.-E., et al. (2026) · Toxicological Sciences · doi:10.1093/toxsci/kfag134
Metadata
- Authors
- Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., Mihai, C., Lynn, A., McFadyen, I., Moore, M. J., Senn, J. J., Stanton, M. G., Almarsson, Ö., Ciaramella, G., & Brito, L. A.
- Affiliations
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Brito, Luis A.
- ORCID
- Venue
- Molecular Therapy — Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 15
- Pages
- 1-11
- ISSN
- 2162-2531 (ISSN-L)
- PMC
- PMC6383180
- OpenAlex
- W2914060533
- Cited by
- 927
- References
- 35
- Citations by year
- 2026: 141 · 2025: 202 · 2024: 162 · 2023: 140 · 2022: 128 · 2021: 114 · 2020: 35 · 2019: 5
- FWCI
- 23.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecular Therapy — Nucleic Acids (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Moderna Therapeutics
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- lipid nanoparticles, mRNA vaccines, intramuscular administration, ionizable lipids, biodegradable lipids, immunogenicity, tolerability, innate immune activation, non-human primates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
